Viking Therapeutics (VKTX) Jefferies Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Healthcare Conference summary
18 Nov, 2026VK2735 maintenance results
At Week 21, weekly VK2735 produced 16.3%–18.7% weight loss across dose groups; the 17.5 mg cohort lost 17.8% (n=118), with no plateau observed.
After switching from weekly dosing, participants maintained up to 96.7% of Week 21 weight loss with every-other-week dosing and up to 90.2% with monthly dosing through Week 33; placebo participants regained ~40% of initial weight loss by Week 12.
Continued 17.5 mg weekly dosing produced 21.7% weight loss from baseline at Week 33, with no plateau observed.
Maintenance-phase GI adverse-event rates were similar to placebo, with low GI event rates after titration; early discontinuation was 3% with every-other-week and 5% with monthly dosing.
ApoB, non-HDL cholesterol and triglyceride effects tracked weight loss and remained consistent through maintenance.
Maintenance studies and dosing options
Part 2 evaluates transition from 17.5 mg weekly subQ to daily oral doses of 10–55 mg; a second study adds six higher-dose subQ arms for every-other-week and monthly dosing, with results expected in 2027 and around mid-year, respectively.
Monthly dosing retention was 90%; 35 mg monthly is being explored in a VANQUISH extension, with data intended for conference presentations and potential label language.
Potential maintenance options include weekly, every-other-week and monthly dosing, or transition from injection to oral therapy; oral maintenance targets retaining at least 75% of initial weight loss, particularly at mid-to-high doses.
A study switching patients from existing injectable treatments to VK2735 is considered worthwhile but is not planned near term.
Longer follow-up is planned in VANQUISH extensions through 52 weeks.
Phase 3 programs and market opportunity
VANQUISH-1 and VANQUISH-2 evaluate weekly subcutaneous VK2735 for 78 weeks; enrollment completed in 4Q25 and 1Q26, respectively, with data expected in 2H27.
SUNRISE-1 and SUNRISE-2 evaluate daily oral VK2735 for 68 weeks in obesity and obesity with diabetes; both began in 4Q26, target 560 participants each, and are expected to report data in 2028.
Four Phase 3 trials are underway; first Phase 3 data are targeted for H2 2027.
The obesity market is projected to exceed $150B by 2035, with a stated 16% CAGR; VK2735 is positioned for oral and injectable use and potential entry as the third obesity franchise.
Latest events from Viking Therapeutics
- VK2735 advances toward obesity commercialization with oral, injectable and maintenance options.VKTX
Corporate presentation - VK2735 Phase 3 advances; $960M liquidity cushions investment and license risk.VKTX
Q3 2026 - VK2735 showed durable weight loss with less-frequent dosing as obesity Phase 3 trials advance.VKTX
Corporate presentation - Up to 22% weight loss and 97% maintenance achieved with flexible, well-tolerated VK2735 dosing.VKTX
Study result - Obesity program VK2735 advances in phase III with broad market and manufacturing strategies.VKTX
Morgan Stanley 24th Annual Global Healthcare Conference - VK2735 delivers up to 14.7% mean weight loss in Phase 2, with Phase 3 trials fully enrolled.VKTX
Corporate presentation - Phase III obesity trials fully enrolled; net loss rose as R&D spending surged, with $502M in cash.VKTX
Q2 2026 - VK2735 delivers up to 15% weight loss in late-stage trials with strong safety and cash reserves.VKTX
Corporate presentation - Q3 net loss rose to $90.8M as R&D spending surged; cash reserves remain strong at $715M.VKTX
Q3 2025